01 July 2009
By:Jim Miller
During the past decade, big pharmaceutical companies have been making major efforts to restructure their manufacturing networks. In their haste to shed costs and assets, however, some may be adding risk to their product supply chains.
 |
01 July 2009
Shirley Dann, Managing Director at SCM Pharma (UK) talks about outsourcing and QbD, and explains why CMOs must focus on what they do well to avoid being left behind.
|
01 June 2009
By:Jim Miller
Is there a point in a CRO's life when contract services begin to look less attractive as a strategic business opportunity? Executives at PPD (NC, USA) seem to think so.
|
01 May 2009
By:Sylvia M Findlay
The CRO market is experiencing two-tiered growth: firstly from pharmaceutical companies seeking to lower fixed costs by outsourcing clinical research to CROs; and secondly, from biotechnology and specialty pharmaceutical companies that lack the infrastructure to conduct trials.
|
01 April 2009
By:Michael Harris
Pharmaceutical Technology Europe (PTE) talks to Michael Harris, Managing Director UK and Ireland Sigma Aldrich and Vice President SAFC, about the company's strategies to overcome industry pressures and accommodate industry trends.
|
01 April 2009
By:Jim Miller
Despite the market downturn and financial meltdown, private equity investors are lining up for pharmaceutical services businesses.
|
01 March 2009
By:Angie Drakulich, Patricia Van Arnum
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role?
|
01 March 2009
By:Angie Drakulich, Patricia Van Arnum
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region?s short? and long?term role?
|
01 March 2009
By:Faiz Kermani
The productivity of the pharma industry has been declining for several years. Could biotechnology reinvigorate drug development?
|
| 
